Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
118.90
+2.53 (+2.17%)
Streaming Delayed Price
Updated: 10:27 AM EDT, Mar 25, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,083,904
Open
117.30
Bid (Size)
118.83 (100)
Ask (Size)
118.92 (100)
Prev. Close
116.37
Today's Range
116.80 - 119.18
52wk Range
73.31 - 125.14
Shares Outstanding
2,531,374,696
Dividend Yield
2.86%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Merck & Co. (MRK) 2026 Analysis: Navigating the Keytruda Cliff with Pipeline-Driven Resilience
Today 9:35 EDT
As of March 25, 2026, Merck & Co., Inc. (NYSE: MRK) stands at a pivotal crossroads in its 135-year history. Known globally as a titan of oncology and vaccines, the Rahway, New Jersey-based...
Via
Finterra
Topics
Artificial Intelligence
Economy
Intellectual Property
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
Today 6:48 EDT
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Performance
YTD
+11.7%
+11.7%
1 Month
-4.0%
-4.0%
3 Month
+13.2%
+13.2%
6 Month
+48.7%
+48.7%
1 Year
+28.8%
+28.8%
More News
Read More
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
Today 6:45 EDT
From
Merck & Co., Inc.
Via
Business Wire
Merck & Co. Inc. (NYSE:MRK) Offers a Steady Dividend Backed by Strong Fundamentals
↗
March 16, 2026
Via
Chartmill
1 S&P 500 Stock to Target This Week and 2 We Ignore
March 24, 2026
Via
StockStory
Topics
Stocks
Bristol-Myers Squibb Shares Jump 3.3% on Robust 2026 Guidance and High Dividend Yield
March 23, 2026
Via
MarketMinute
Topics
Economy
Initial Public Offering
Intellectual Property
Pfizer vs Moderna: Which Pharma Stock Has More Upside?
↗
March 19, 2026
Via
The Motley Fool
Topics
Intellectual Property
FDA Approves BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) from Merck Animal Health to Treat and Control Asian Longhorned Tick and Gulf Coast Tick for 12 Months in Dogs
March 18, 2026
From
Merck & Co., Inc.
Via
Business Wire
The High-Stakes Gambit: How Healthcare Giants are 'Front-Loading' Megadeals to Outrun Regulatory Storms
March 18, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Intellectual Property
The Grand Divergence: Finance Surges as Health Care Braces for a Historic Q1 Earnings Slump
March 17, 2026
Via
MarketMinute
Topics
Earnings
Economy
Initial Public Offering
Merck to Present New Data Reinforcing Long-Term Efficacy of GARDASIL®9 and GARDASIL® at the EUROGIN International Multidisciplinary HPV Congress 2026
March 17, 2026
From
Merck Sharp & Dohme
Via
Business Wire
The mRNA Renaissance: Moderna’s 83% Surge Leads the 2026 Healthcare Recovery
March 16, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Initial Public Offering
Stocks
Merck & Co. Trades Ex-Dividend as Healthcare Emerges as a Volatility Hedge in 2026
March 16, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Intellectual Property
Merck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance Innovative Research
March 16, 2026
From
Merck & Co., Inc.
Via
Business Wire
1 ETF That Could Turn $100 Per Month Into $67,380
↗
March 15, 2026
Via
The Motley Fool
Topics
ETFs
Economy
World Trade
Flight to Quality: JPMorgan and Eli Lilly Emerge as Defensive Anchors Amid Geopolitical Storm
March 13, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Stocks
The Dividend Shield: How Meta, Microsoft, Merck, and Target are Signal-Boosting Balance Sheet Strength in a Cooling 2026 Economy
March 13, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Workforce
1 Unpopular Stock That Deserves Some Love and 2 We Avoid
March 13, 2026
Via
StockStory
BioNTech Navigates Post-Pandemic Deficit: A €17 Billion Bet on the Oncology Frontier
March 10, 2026
Via
MarketMinute
Pfizer (PFE) 2026 Research Feature: The High-Stakes Pivot to Oncology and Obesity
March 10, 2026
Via
Finterra
Topics
Economy
Intellectual Property
Lawsuit
2 Dow Jones Stocks to Research Further and 1 Facing Headwinds
March 09, 2026
Via
StockStory
Topics
Stocks
1 Dividend Stock to Buy Hand Over Fist and 1 to Avoid
↗
March 08, 2026
Via
The Motley Fool
Topics
Intellectual Property
3 Undervalued Names Too Cheap to Ignore
↗
March 07, 2026
Via
MarketBeat
The Moderna Pivot: Analyzing the 14% Surge and the Future of mRNA Oncology
March 06, 2026
Via
Finterra
Topics
Initial Public Offering
Intellectual Property
Forget ImmunityBio: This Big‑Cap Pharma Is the Safer Play on Next‑Gen Cancer Therapies
↗
March 05, 2026
Via
The Motley Fool
Frequently Asked Questions
Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 118.90
When was Merck & Co last traded?
The last trade of Merck & Co was at 03/25/26 10:27 AM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 300.98B
How many shares of Merck & Co are outstanding?
Merck & Co has 301B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
